In8bio, Inc. (INAB) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, In8bio reported revenue of $0. Net income was -$19.4M, or -$4.44 per diluted share. Operating activities generated -$12.7M of cash. At fiscal year end, In8bio held $32.3M in total assets against $4.7M in total liabilities.
Open the full interactive In8bio financials → Quarterly statements, key ratios, valuation history and price charts.
In8bio Key Stats
| Share Price | $1.18 |
|---|---|
| Market Cap | $23.0M |
| 52-Week Range | $0.96 – $2.59 |
| Shares Outstanding | 19.5 million (basic, 2026 Q2) |
In8bio Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$14.7M | -$28.5M | -$30.3M | -$30.4M | -$19.4M |
| Pre-Tax Income | -$14.7M | -$28.5M | -$30.0M | -$30.4M | -$19.4M |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$14.7M | -$28.5M | -$30.0M | -$30.4M | -$19.4M |
| Diluted EPS | -$44.10 | -$40.80 | -$30.00 | -$17.10 | -$4.44 |
In8bio Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$3.9M | -$4.9M | -$5.1M | -$4.8M |
| Diluted EPS | -$0.85 | -$1.13 | -$0.26 | -$0.25 |
In8bio Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Current Assets | $39.0M | $22.2M | $24.6M | $12.6M | $27.9M |
| Total Assets | $42.2M | $33.0M | $33.7M | $20.9M | $32.3M |
| Current Liabilities | $2.3M | $5.8M | $5.4M | $3.1M | $3.2M |
| Total Liabilities | $4.0M | $10.3M | $8.8M | $6.5M | $4.7M |
| Shareholders' Equity | $38.2M | $22.7M | $24.9M | $14.5M | $27.6M |
In8bio Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$13.5M | -$24.1M | -$23.3M | -$24.1M | -$12.7M |
| Cash From Investing | -$309,000 | -$3.7M | -$600,000 | -$187,000 | $0 |
| Cash From Financing | $33.0M | $9.0M | $27.0M | $14.2M | $28.6M |
Figures from In8bio's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full In8bio financials page for every line item.
In8bio Company Profile
| Ticker | INAB |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001740279 |
Frequently Asked Questions
What was In8bio's revenue in fiscal 2025?
In8bio (INAB) reported revenue of $0 for fiscal 2025.
What is In8bio's annual revenue history?
In8bio's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was In8bio's net income in fiscal 2025?
In8bio reported net income of -$19.4M for fiscal 2025.
What was In8bio's earnings per share (EPS) in fiscal 2025?
In8bio's diluted EPS was -$4.44 for fiscal 2025 (adjusted for any later stock splits).
What was In8bio's revenue last quarter?
In its most recent reported quarter (2026 Q2), In8bio reported revenue of $0.
How many shares of In8bio are outstanding?
In8bio reported a weighted average of 19.5 million basic shares outstanding in 2026 Q2.
What is In8bio's market cap?
Based on its latest closing price, In8bio (INAB) has a market capitalization of about $23.0M.
When does In8bio's fiscal year end?
In8bio's fiscal year end, as registered with the SEC, is December 31.
Where is In8bio headquartered?
In8bio lists its business address in New York, New York in its SEC filings.